3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis.
Chemo-radiotherapy
Cisplatin
Dose
Head and neck squamous carcinoma
Treatment
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
11 Feb 2019
11 Feb 2019
Historique:
received:
29
11
2018
accepted:
04
02
2019
entrez:
13
2
2019
pubmed:
13
2
2019
medline:
2
4
2019
Statut:
epublish
Résumé
Concurrent chemoradiotherapy with cisplatin is standard for patients (pts) with loco-regionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) and for patients with resected SCCHN with high-risk features. The standard regimen includes 3-weekly cisplatin, but weekly regimens are often used to lower toxicity. Reaching a cumulative dose of ≥200 mg/m Multicentre, retrospective analysis of all patients undergoing combined RCT with cisplatin treated at 3 centres in Switzerland between 06/2008 and 12/2015. Three hundred fourteen pts. were included (3-weekly, N = 127; weekly, N = 187). Median cumulative cisplatin dose was 200 mg/m Significantly more patients receive a cumulative cisplatin dose of ≥200 mg/m
Sections du résumé
BACKGROUND
BACKGROUND
Concurrent chemoradiotherapy with cisplatin is standard for patients (pts) with loco-regionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) and for patients with resected SCCHN with high-risk features. The standard regimen includes 3-weekly cisplatin, but weekly regimens are often used to lower toxicity. Reaching a cumulative dose of ≥200 mg/m
METHODS
METHODS
Multicentre, retrospective analysis of all patients undergoing combined RCT with cisplatin treated at 3 centres in Switzerland between 06/2008 and 12/2015.
RESULTS
RESULTS
Three hundred fourteen pts. were included (3-weekly, N = 127; weekly, N = 187). Median cumulative cisplatin dose was 200 mg/m
CONCLUSIONS
CONCLUSIONS
Significantly more patients receive a cumulative cisplatin dose of ≥200 mg/m
Identifiants
pubmed: 30744643
doi: 10.1186/s13014-019-1235-y
pii: 10.1186/s13014-019-1235-y
pmc: PMC6371614
doi:
Substances chimiques
Antineoplastic Agents
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Références
Head Neck. 2001 Jul;23(7):579-89
pubmed: 11400247
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):365-73
pubmed: 15380568
J Clin Oncol. 2004 Dec 1;22(23):4665-73
pubmed: 15534360
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
BMC Cancer. 2006 Jan 31;6:28
pubmed: 16448551
Lancet Oncol. 2007 Jul;8(7):613-24
pubmed: 17543584
J Cancer Res Ther. 2006 Jul-Sep;2(3):100-4
pubmed: 17998687
Acta Oncol. 2008;47(8):1513-8
pubmed: 18607863
Cancer Chemother Pharmacol. 2009 Aug;64(3):601-5
pubmed: 19123002
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Head Neck Oncol. 2009 Jun 15;1:17
pubmed: 19527507
Am J Clin Oncol. 2009 Oct;32(5):488-91
pubmed: 19528791
Head Neck. 2010 May;32(5):599-606
pubmed: 19757422
Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):13-20
pubmed: 1993621
Ann Oncol. 2010 Nov;21(11):2272-7
pubmed: 20427350
Oncologist. 2010;15(9):921-3
pubmed: 20798197
Clin Oncol (R Coll Radiol). 2011 Mar;23(2):134-40
pubmed: 21030225
Jpn J Clin Oncol. 2011 Aug;41(8):980-6
pubmed: 21715362
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Oral Oncol. 2012 Mar;48(3):266-71
pubmed: 22079100
Radiat Oncol. 2012 Dec 18;7:215
pubmed: 23245290
J Clin Oncol. 2013 Feb 10;31(5):543-50
pubmed: 23295795
Oral Oncol. 2014 Apr;50(4):311-8
pubmed: 24467937
Jpn J Clin Oncol. 2014 Aug;44(8):770-4
pubmed: 24842866
Head Neck. 2016 Feb;38(2):202-7
pubmed: 25224814
J Clin Oncol. 2014 Dec 1;32(34):3858-66
pubmed: 25366680
Head Neck. 2016 Apr;38 Suppl 1:E2151-8
pubmed: 25735803
Drug Des Devel Ther. 2015 Nov 26;9:6203-10
pubmed: 26648696
BMC Cancer. 2016 Jul 08;16:437
pubmed: 27391309
Oral Oncol. 2016 Aug;59:43-49
pubmed: 27424181
Eur J Cancer. 2016 Nov;67:174-182
pubmed: 27669504
J Clin Diagn Res. 2017 Jan;11(1):XC07-XC11
pubmed: 28274031
Laryngoscope. 2018 Jul;128(7):1582-1588
pubmed: 29086431
J Clin Oncol. 2018 Apr 10;36(11):1064-1072
pubmed: 29220295
Oral Oncol. 2018 Jan;76:52-60
pubmed: 29290286
Acta Oncol. 2018 Sep;57(9):1143-1151
pubmed: 29447088
Acta Oncol. 1994;33(7):825-30
pubmed: 7993653
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004
pubmed: 8985019
Radiother Oncol. 1997 Apr;43(1):29-37
pubmed: 9165134